Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.
You may also be interested in...
OTC Monograph Offers Redemption For Some Unapproved Cough/Cold Drugs
FDA could seize offending products or file injunctions against firms if the drugs were not listed with the agency before March 2 and firms do not discontinue production and shipping immediately.
OTC Monograph Offers Redemption For Some Unapproved Cough/Cold Drugs
FDA could seize offending products or file injunctions against firms if the drugs were not listed with the agency before March 2 and firms do not discontinue production and shipping immediately.
Pediatric Cough/Cold Products Relabeled “Do Not Use” For Children Under 4
Voluntary effort based on AE data for 2-3-year-olds.